Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AGRX

AGRX - Agile Therapeutics Inc Stock Price, Fair Value and News

0.81USD-0.08 (-8.99%)Market Closed
Watchlist

Market Summary

USD0.81-0.08
Market Closed
-8.99%

AGRX Stock Price

View Fullscreen

AGRX RSI Chart

AGRX Valuation

Market Cap

2.2M

Price/Earnings (Trailing)

-0.16

Price/Sales (Trailing)

0.11

EV/EBITDA

0.05

Price/Free Cashflow

-0.2

AGRX Price/Sales (Trailing)

AGRX Profitability

Operating Margin

57.74%

EBT Margin

-69.73%

Return on Equity

-3.43%

Return on Assets

-127.9%

Free Cashflow Yield

-505.87%

AGRX Fundamentals

AGRX Revenue

Revenue (TTM)

20.0M

Rev. Growth (Yr)

121.92%

Rev. Growth (Qtr)

21.06%

AGRX Earnings

Earnings (TTM)

-13.9M

Earnings Growth (Yr)

86.53%

Earnings Growth (Qtr)

79.02%

Breaking Down AGRX Revenue

Last 7 days

2.6%

Last 30 days

-35.8%

Last 90 days

-41.7%

Trailing 12 Months

-91.1%

How does AGRX drawdown profile look like?

AGRX Financial Health

Current Ratio

0.57

Debt/Equity

0.04

Debt/Cashflow

-0.69

AGRX Investor Care

Shares Dilution (1Y)

209.21%

Diluted EPS (TTM)

84.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202312.9M16.3M20.0M0
20225.7M6.7M8.4M10.9M
20211.6M2.5M3.3M4.1M
2020000749.0K

Tracking the Latest Insider Buys and Sells of Agile Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 03, 2023
coiante scott m
acquired
-
-
20,000
chief financial officer
Jun 28, 2023
gilmore geoffrey
acquired
-
-
20,216
chief administrative officer
Jun 28, 2023
welsh amy
acquired
-
-
13,500
chief commercial officer
Jun 28, 2023
altomari alfred
acquired
-
-
46,463
chief executive officer
Jun 28, 2023
conway robert g
acquired
-
-
13,500
chief supply chain officer
Jun 28, 2023
korner paul
acquired
-
-
13,500
chief medical officer
Jun 08, 2023
fischer seth h. z.
acquired
-
-
935
-
Jun 08, 2023
torrente josephine
acquired
-
-
935
-
Jun 08, 2023
hubbard john w
acquired
-
-
935
-
Jun 08, 2023
carson sandra
acquired
-
-
935
-

1–10 of 50

Which funds bought or sold AGRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
unchanged
-
-4,988
21,144
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
unchanged
-
-4.00
20.00
-%
Feb 14, 2024
COMERICA BANK
unchanged
-
-2.00
8.00
-%
Feb 14, 2024
INVESTOR AB
new
-
3,420
3,420
-%
Feb 14, 2024
VANGUARD GROUP INC
new
-
39,930
39,930
-%
Feb 14, 2024
Royal Bank of Canada
added
214
1,000
2,000
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
50.07
6,624
37,532
-%
Feb 13, 2024
RENAISSANCE TECHNOLOGIES LLC
new
-
115,000
115,000
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
-20.00
88.00
-%

1–10 of 28

Are Funds Buying or Selling AGRX?

Are funds buying AGRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGRX
No. of Funds

Unveiling Agile Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
lind global fund ii lp
1.8%
44,750
SC 13G/A
Feb 06, 2024
intracoastal capital, llc
0.9%
23,961
SC 13G/A
Feb 14, 2023
perceptive advisors llc
0%
0
SC 13G/A
Feb 13, 2023
lind global fund ii lp
9.9%
4,459,759
SC 13G/A
Feb 08, 2023
intracoastal capital, llc
6.3%
2,730,000
SC 13G/A
Jul 12, 2022
lind global fund ii lp
9.9%
3,250,223
SC 13G
Jul 11, 2022
intracoastal capital, llc
9.99%
3,430,345
SC 13G
Feb 14, 2022
perceptive advisors llc
17.5%
21,294,485
SC 13G/A
Feb 09, 2022
vanguard group inc
3.70%
4,494,704
SC 13G/A
Jul 12, 2021
blackrock inc.
1.5%
1,308,650
SC 13G/A

Recent SEC filings of Agile Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
8-K
Current Report
Feb 23, 2024
424B5
Prospectus Filed
Feb 23, 2024
424B5
Prospectus Filed
Feb 15, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
S-1/A
Initial Public Offering
Feb 06, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
S-1/A
Initial Public Offering
Feb 02, 2024
S-1/A
Initial Public Offering
Dec 20, 2023
S-1/A
Initial Public Offering

Peers (Alternatives to Agile Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.7B
93.0B
-3.60% -2.76%
11.09
4.19
6.46% 95.94%
156.7B
46.5B
-3.76% -37.06%
-112.85
3.37
42.59% -114.62%
155.0B
28.2B
-7.44% 18.02%
23.07
5.5
7.09% 2.52%
91.6B
27.1B
-17.13% -16.65%
16.18
3.38
-0.60% 23.36%
14.4B
15.8B
15.02% 26.90%
-25.85
0.91
6.17% 77.01%
MID-CAP
4.9B
1.7B
14.11% 18.79%
13.89
2.97
49.61% 324.78%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.4B
8.8B
-0.23% 18.85%
-5.66
0.38
7.79% -163.11%
2.6B
601.3M
-0.28% 70.16%
18.91
4.26
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.91
1.86
16.26% -147.49%
24.9M
84.1M
58.23% -28.98%
-1.17
0.22
2882.68% -145.15%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
16.2M
111.1M
-6.33% -18.68%
-1.02
0.15
-10.43% 84.90%
2.2M
20.0M
-35.83% -91.10%
-0.16
0.11
137.71% 66.04%

Agile Therapeutics Inc News

Latest updates
Investing.com22 Feb 202404:02 pm
InvestorPlace22 Feb 202412:57 pm
InvestorsObserver20 Feb 202412:52 pm

Agile Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue21.1%6,662,0005,503,0003,813,0003,995,5003,002,0002,126,0001,761,0001,513,5001,287,0001,185,000116,000749,000
Cost Of Revenue7.4%2,477,0002,307,0002,003,0001,653,0001,425,0002,231,0001,527,0005,701,0002,711,0001,145,0001,161,000-
Gross Profit30.9%4,185,0003,196,0001,810,0002,342,5001,577,000-105,000234,000-4,187,500-1,424,00040,000-1,045,000467,000
Operating Expenses-1.6%8,185,0008,322,0008,518,0009,220,00020,285,00011,293,00015,807,00018,170,50014,350,00016,691,00015,177,00017,208,000
  S&GA Expenses5.0%4,800,0004,570,0004,670,0006,845,5005,560,0007,411,00010,553,00013,004,5009,386,00011,977,0009,253,00010,698,500
  R&D Expenses0.3%705,000703,000763,000352,000788,000856,0001,257,0001,673,0001,593,000862,0002,123,0003,012,000
EBITDA Margin39.5%-0.61-1.02-1.31-2.36-4.79-7.59-10.97-15.87-19.09-25.49-35.27-64.94
Interest Expenses-8.3%341,000372,000402,000432,0001,004,000823,000872,0001,000,000999,000993,000922,000904,000
Income Taxes--------4,675,000-----
Earnings Before Taxes79.0%-799,000-3,809,000-5,390,000-3,930,000-5,930,000-5,168,000-15,060,000-19,530,000-16,772,000-17,637,000-17,128,000-17,620,000
EBT Margin40.3%-0.70-1.17-1.58-2.76-5.44-8.45-12.01-17.33-20.72-27.45-37.91-69.23
Net Income79.0%-799,000-3,809,000-5,389,000-3,930,000-5,930,000-5,168,000-10,385,000-19,530,000-16,772,000-17,637,000-17,128,000-17,620,000
Net Income Margin40.3%-0.70-1.17-1.58-2.33-4.88-7.75-11.19-17.33-20.72-27.45-37.91-69.23
Free Cashflow104.3%365,000-8,519,000-1,595,000-1,559,000-16,703,000-2,941,000-14,877,000-16,673,000-18,645,000-15,414,000-14,739,000-17,399,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-13.4%11.0013.0014.0014.0018.0033.0029.0039.0037.0052.0059.0073.0089.0010310950.0034.0025.0026.0022.0032.00
  Current Assets-13.6%10.0012.0011.0011.0015.0018.0014.0024.0022.0037.0044.0057.0073.0089.0095.0035.0020.0011.0012.008.0018.00
    Cash Equivalents3.2%3.003.004.005.006.0013.004.0019.0015.0026.0016.0014.0024.0039.0094.0034.0018.0011.0012.008.0017.00
  Inventory-5.0%2.003.002.001.002.002.003.001.003.003.002.00----------
  Net PPE-19.8%0.000.000.000.000.0012.0012.0012.0013.0013.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.0014.00
Liabilities-5.6%23.0025.0023.0020.0021.0030.0035.0035.0026.0028.0024.0024.0023.0022.0018.004.003.003.003.002.005.00
  Current Liabilities14.6%18.0015.0019.0013.0012.0029.0026.0029.0010.0012.009.007.007.006.003.004.002.002.001.002.008.00
  Long Term Debt---------16.0016.0016.0016.0016.0016.0015.00------
    LT Debt, Current1.7%2.002.002.001.001.0013.0012.0017.00-------------
Shareholder's Equity0.1%4064064054034022.003884.0011.0025.0035.0049.0066.0081.0091.0046.0028627327120.0023.00
  Retained Earnings-0.2%-418-417-414-408-404-398-393-383-364-346-329-312-294-279-268-260-254-249-246-241-237
  Additional Paid-In Capital0.1%406406405403402401388387374372364362361360359306286273271262261
Shares Outstanding38.8%2.002.00-1.000.000.000.000.000.000.000.000.000.00--------
Float------14.00---101---197---52.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations104.3%365-8,519-1,595-1,559-16,703-2,934-14,751-16,618-18,580-15,336-14,668-17,342-15,320-6,765-7,884-3,270-5,080-2,378-4,961-3,136-3,851
  Share Based Compensation-8.7%439481498524536669764866887843742711647839621415378479490803721
Cashflow From Investing-------7.00-126-55.004,93518,39516,1857,527-173-47,880-164-68.00-----2.00
Cashflow From Financing-104.0%-2786,8757786609,82112,225-52321,0812,2626,59548411521016667,49419,44712,8941,4048,670-5,939-1,686

AGRX Income Statement

2023-09-30
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statements of Operations and Comprehensive Loss    
Revenues, net$ 6,662$ 3,002$ 15,979$ 6,888
Cost of product revenues2,4771,4256,7875,183
Gross profit4,1851,5779,1921,705
Operating expenses:    
Research and development7057882,1712,901
Selling and marketing4,8005,56014,04023,523
General and administrative2,6802,8158,8139,837
Loss on disposition of assets 11,122 11,122
Total operating expenses8,18520,28525,02447,383
Loss from operations(4,000)(18,708)(15,832)(45,678)
Other income (expense)    
Interest income13466150
Interest expense(341)(1,004)(1,114)(2,699)
Unrealized gain on warrant liability3,52913,7366,89022,171
Total other income, net3,20112,7785,83719,522
Loss before benefit from income taxes(799)(5,930)(9,995)(26,156)
Benefit from income taxes   4,675
Net loss and comprehensive loss$ (799)$ (5,930)$ (9,995)$ (21,481)
Net loss per share (basic) (in dollars per share)$ (0.27)$ (8.01)$ (5.30)$ (71.61)
Net loss per share (diluted) (in dollars per share)$ (0.27)$ (8.01)$ (5.30)$ (71.61)
Weighted-average common shares (basic) (in shares)2,950,136739,9571,884,793299,970
Weighted-average common shares (diluted) (in shares)2,950,136739,9571,884,793299,970

AGRX Balance Sheet

2023-09-30
Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 2,873$ 5,246
Accounts receivable, net3,5213,377
Inventory, net2,4111,332
Prepaid expenses and other current assets1,2591,403
Total current assets10,06411,358
Property and equipment, net101177
Right of use asset486695
Other non-current assets2382,012
Total assets10,88914,242
Current liabilities:  
Long-term debt, current portion1,5891,426
Notes payable, current portion379 
Accounts payable6,8797,734
Accrued expenses8,3383,908
Lease liability, current portion353319
Total current liabilities17,53813,387
Lease liabilities, long-term196466
Warrant liability5,5665,934
Total liabilities23,30019,787
Commitments and contingencies (Note 10)
Stockholders' deficit  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at September 30, 2023 and no shares issued and outstanding at December 31, 2022
Common stock, $0.0001 par value, 300,000,000 shares authorized, 2,277,657 and 859,402 issued and outstanding at September 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital406,288403,157
Accumulated deficit(418,699)(408,702)
Total stockholders' deficit(12,411)(5,545)
Total liabilities and stockholders' deficit$ 10,889$ 14,242
AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEwww.agiletherapeutics.com
 EMPLOYEES22

Agile Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Agile Therapeutics Inc? What does AGRX stand for in stocks?

AGRX is the stock ticker symbol of Agile Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agile Therapeutics Inc (AGRX)?

As of Fri Feb 23 2024, market cap of Agile Therapeutics Inc is 2.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers. The fair value of Agile Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agile Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agile Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGRX is over valued or under valued. Whether Agile Therapeutics Inc is cheap or expensive depends on the assumptions which impact Agile Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGRX.

What is Agile Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, AGRX's PE ratio (Price to Earnings) is -0.16 and Price to Sales (PS) ratio is 0.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGRX PE ratio will change depending on the future growth rate expectations of investors.